The ARTS-DN (MinerAlocorticoid Receptor antagonist Tolerability Study in Diabetic Nephropathy) comparing finerenone versus placebo documented a dose-dependent reduction in albuminuria at 90 days without a significant impact on eGFR decline (15). The gene discussed is NR3C2; the disease is diabetic kidney disease.